Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

A 22-year-old shared his 15-month progress using finasteride and 12-month progress with minoxidil for hair loss, noting improved thickness but minimal hairline change. He experienced initial shedding with minoxidil but no side effects from finasteride, and he advises patience and consistency for results.

Long-term finasteride users report that the drug may lose effectiveness over time, with some considering switching to dutasteride or adding minoxidil to their regimen. Many users suggest hair transplants or adjusting treatments to manage hair loss progression.

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

The user has been using oral minoxidil, dutasteride, RU58841, and other treatments for hair loss over nine months, seeing some improvement in hair thickness and crown volume but continued thinning at the hairline. They plan to continue treatment for another nine months despite being sensitive to DHT fluctuations and are considering increasing dosages or other options like a hair transplant.

A 22-year-old male shared his positive experience using 1 mg finasteride daily for two years, noting significant hair thickening and texture improvement without side effects. Other users discussed their own hair loss treatments, including finasteride and minoxidil, and shared encouragement and advice.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

The conversation humorously speculates that bald Grey Aliens might be future humans who haven't solved baldness, despite advanced technology. Treatments like microneedling, minoxidil, and finasteride are mentioned as potential solutions.

The user experienced side effects from finasteride and Nutrafol, opting for non-hormonal treatments like minoxidil, exercise, and a healthy lifestyle. Others discussed using Dutasteride, Biotin, and minoxidil with varying success and side effects.

Balding is challenging, and relying on medications like finasteride is often seen as a better option than constantly shaving or trying to compensate in other areas. Many feel that societal expectations to "own it" or drastically change oneself to cope with baldness are unrealistic and burdensome.

Finasteride can reduce semen volume due to prostate shrinkage but doesn't affect fertility. To increase semen volume, consider zinc, lecithin, and reducing finasteride dosage.

Access to minoxidil and finasteride in prison is unlikely unless prescribed for medical conditions like hypertension or benign prostatic hyperplasia. Cosmetic treatments are generally not provided in prison.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

Finasteride may cause sleep disturbances, with some users experiencing insomnia. Reducing the dosage, switching brands, or trying Dutasteride might help.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

Be skeptical of claims about new baldness cures; current treatments like finasteride, dutasteride, and minoxidil remain the best options. New products like Breezula and PP405 lack compelling evidence and may not be available soon.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

User uses Indian hair serum with procapil and procyanidin b2, stopped minoxidil due to allergies. Seeks advice on hair wash techniques and products for shoulder-length hair and scalp care while using hair growth serums.

A serum containing Centella asiatica extracellular vesicles, IGF-1, FGF-7, and caffeine significantly improved hair thickness, density, length, and reduced hair loss after 56 days. The conversation also discusses how treatments like finasteride, minoxidil, and ketoconazole address different aspects of hair loss by reducing DHT, improving blood flow, and lowering inflammation.